Deciphering Gene Expression Profiling in Cardiac Resynchronization Therapy
نویسندگان
چکیده
منابع مشابه
gene expression profiling for cancer targeted therapy
background : lung cancer is still the leading cause of cancer- related deaths and most of themâ are normally diagnosed in late stages, so there is an urgent need to establish reliable tools for the identification at early stages of the disease. in this study, we use an eleven gene signature test to examine lung biopsy specimens for diagnostic, prognostic & therapeutic purposes. methods : bronc...
متن کاملDeciphering poxvirus gene expression by RNA sequencing and ribosome profiling.
UNLABELLED The more than 200 closely spaced annotated open reading frames, extensive transcriptional read-through, and numerous unpredicted RNA start sites have made the analysis of vaccinia virus gene expression challenging. Genome-wide ribosome profiling provided an unprecedented assessment of poxvirus gene expression. By 4 h after infection, approximately 80% of the ribosome-associated mRNA ...
متن کاملCardiac-resynchronization therapy.
Cardiac resynchronization therapy (CRT) addresses abnormal left ventricular (LV) activation that produces detrimental effects on cardiac systolic and diastolic function. CRT improves symptoms and ventricular performance, promotes reverse remodeling, and decreases mortality and hospitalization in patients with congestive heart failure (CHF). Atrial-synchronized biventricular stimulation reverses...
متن کاملCardiac Resynchronization Therapy
According to the 2013 update on heart disease statistics from American Heart Association, an estimated 5.1 million Americans ≥20 years of age have a diagnosis of heart failure. In the year 2009, heart failure was noted to be the primary cause of death in >56 000 people and contributed to death of >274 000 people. It is one of the most common causes of hospitalization in patients ≥65 years of ag...
متن کامل[Cardiac resynchronization therapy].
Fifteen years after the birth of resynchronization therapy, this technique has become one of the recommended treatments in severe heart failure patients, with low ejection fraction (4 35%), and conduction disorders (ORS > or = 120 ms). Based on large randomized clinical trials, the European recommendation is class I type (level of evidence A), to improve symptoms and survival of this patient po...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the American College of Cardiology
سال: 2008
ISSN: 0735-1097
DOI: 10.1016/j.jacc.2008.04.072